Toxicogenomics – A Drug Development Perspective - Genomic Biomarkers for Pharmaceutical Development - page 147

[107] Winnike JH, et al. Use of pharmaco-metabolomics for early prediction of acetaminophen-induced hepatotox-
icity in humans. Clin Pharmacol Ther 2010;88(1):45-51.
[108] FDA guidance for industry, E16 biomarkers related to drug or biotechnology product development' context,
structure, and format of qualification submissions. August 2011 ICH.
[109] Scannell JW, et al. Diagnosing the decline in pharmaceutical R&D eficiency. Nat Rev Drug Discov
2012;11(3):191-200.
[110] Chen MJ, et al. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci
2012;130(2):217-28.
[111] Choudhuri S. Looking back to the future: from the development of the gene concept to toxicogenomics.
Toxicol Mech Methods 2009;19(4):263-77.
[112] Wei T, Li SY. Development of genomics-based gene expression signature biomarkers in oncology and toxicol-
ogy to facilitate drug discovery and translational medicine. Curr Bioinformatics 2010;5(2):109-17.
[113] Ryan TP, Stevens JL, Thomas CE. Strategic applications of toxicogenomics in early drug discovery. Curr Opin
Pharmacol 2008;8(5):654-60.
[114] Stevens J. Strategic application of toxicogenomics in early drug discovery. Drug Metab Rev 2010;42:3-4.
[115] Bates S. The role of gene expression proiling in drug discovery. Curr Opin Pharmacol 2011;11(5):549-56.
[116] Sirota M, et al. Discovery and preclinical validation of drug indications using compendia of public gene
expression data (vol 3, 96ra77, 2011). Sci Transl Med 2011;3(102):96ra77.
[117] Lord PG, Nie A, McMillian M. The evolution of gene expression studies in drug safety assessment (vol 16, pg
51, 2006). Toxicol Mech Methods 2006;16(4):241.
[118] Ulrich R. Applications of gene expression proiling to evaluating drug metabolism and safety. Drug Metab
Rev 2005;37:7.
[119] Harrill AH, Ross PK, Gatti DM, Threadgill DW, Rusyn I. Population-based discovery of toxicogenomics bio-
markers for hepatotoxicity using a laboratory strain diversity panel. Toxicol Sci 2009;110(1):235-43.
[120] Kiyosawa N, Ando Y, Manabe S, Yamoto T. Toxicogenomic biomarkers for liver toxicity. J Toxicol Pathol
2009;22(1):35-52.
[121] Uehara T, et al. The japanese toxicogenomics project: application of toxicogenomics. Mol Nutr Food Res
2010;54(2):218-27.
[122] Zhang M, Chen MJ, Tong WD. Is toxicogenomics a more reliable and sensitive biomarker than conventional
indicators from rats to predict drug-induced liver injury in humans? Chem Res Toxicol 2012;25:1.
[123] Huang J, Shi W, et al. Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics
J 2010;10:353-63.
[124] Kerns RTB, Bushel PR. The impact of classiication of interest on predictive toxicogenomics. Front Genet
2012;3(14).
[125] Chen MJ, et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today
2011;16(15-16):697-703.
[126] Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab
Toxicol 2011;7(7):8 7 5-90.
[127] Lucena MI, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the inluence of age
and sex. Hepatology 2009;49(6):2001-9.
[128] Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and
outcomes. Cell Biochem Biophys 2012;64(2):77-83.
[129] Carey EJ, et al. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci
2008;53(7):1977-82.
[130] Lee WM. Medical progress: drug-induced hepatotoxicity. N Engl J Med 2003;349(5):474-85.
[131] Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective
study. Hepatology 2010;52(6):2065-76.
[132] McDonnell ME, Braverman LE. Drug-related hepatotoxicity. N Engl J Med 2006;354(20):2191.
[133] Navarro VJ, Senior JR. Current concepts - Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731-9.
[134] Lee WM. Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol 2012;26(1):3-16.
[135] Lee WM. Acute liver failure. Semin Respir Crit Care Med 2012;33(1):36-45.
[136] FDA guidance for industry, Drug-induced liver injury: premarketing clinical evaluation. July 2009 Drug
Safety.
[137] Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30(4):277-94.